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Dear Editor,
We read with interest the recent report by Montgomery
and Booth, who described a case of methemoglobinemia in a
50-year-old, G6PD-deficient African American man with
newly diagnosed T-cell lymphoblastic leukemia being treated
with rasburicase for tumor lysis syndrome.1 Due to ongoing
hemolysis and refractory hypoxia, the authors performed a
one blood volume erythrocytapheresis with a 45% decrease
in methemoglobin (14.6%–8%). Surprisingly, the patient
continued to be hypoxic with subjective dyspnea, bilateral
pleural effusions, and mildly elevated methemoglobin levels
(7.5–11%) for 36 h post-exchange. We would like to share
our experience in a nearly identical patient several years ago,
in whom we observed an immediate improvement in symp-
toms following erythrocytapheresis.
The patient was a 64 kg, 15-year-old African-American
male with a 2-week history of fever, Bell’s palsy, lymphade-
nopathy, nausea, and abdominal pain due to new T-cell lym-
phoblastic leukemia. His initial laboratories showed a mildly
elevated WBC count (11.6 K/lL, range 13.7–17) with 40%
circulating blasts, anemia (hemoglobin 11.4 g/dL), elevated
lactate dehydrogenase ([LDH] 8375 IU/L, range 120–240
IU/L), hyperuricemia (29.5 mg/dL, range 3.5–7.8), and acute
renal failure (creatinine 4.8 mg/dL, range, 8–20). While in
the emergency room, he received 6 mg rasburicase for tumor
lysis syndrome. Within 3 h of receiving rasburicase, he be-
came hypoxic with O2 saturation 70-80% despite escalating
O2 supplementation, accompanied by falling hemoglobin
and methemoglobinemia (16%, range 0–1.5%). The patient
was transfused 1 unit RBC and given a 25% test dose of
methylene blue with no clinical improvement, worsening
anemia, tachypnea (21–27 breaths/minute), and ongoing
methemoglobinemia. Within 12 h of admission, the patient
required intubation with O2 saturations5 60% on 100%
FiO2, methemoglobin5 23%, lactate5 5 mmol/L (range,
0.4–2.2), hemoglobin5 7.9 g/dL, LDH5 12,699 IU/L, and
acidosis (pH5 7.2). The patient subsequently underwent
emergent erythrocytapheresis for methemoglobinemia and
presumed G6PD-deficiency. The procedure was performed
on a COBE Spectra at a whole blood: anticoagulant ratio of
7:1, 30% fraction cell remaining, an end hematocrit of 30%,
and 8 units group O RBC (2693 mL) for replacement. The
patient had a brisk clinical response to erythrocytapheresis
with O2 saturations >90% by the end of the procedure. He
was extubated approximately 4 h post-procedure with a
methemoglobin5 5% and O2 saturation5 95% on 2 L sup-
plemental oxygen. By day 3, the patient had normal O2 satu-
ration on room air and a methemoglobin5 2.3%. Subsequent
testing confirmed that the patient was G6PD-deficient.
This is the fifth report of refractory methemoglobinemia
treated by either whole-blood exchange or erythrocytapheresis,1–4
and the third case following rasburicase administration in
G6PD-deficient patients.1,2 Like carbon monoxide poisoning,
methemoglobinemia causes a left-shift in the O2 dissociation
curve, leading to a progressive and refractory hypoxia that is
exacerbated and amplified in the setting of anemia.5 Patients
with symptomatic methemoglobinemia are typically treated
with supplemental oxygen, RBC transfusion, and methylene
blue, which helps restore glutathione levels. In G6PD-
deficient patients, however, methylene blue can independently
precipitate hemolysis and methemoglobinemia. This case
shows a prompt improvement in oxygenation with erythrocy-
tapheresis in the setting of methemoglobinemia and G6PD-
deficiency,2,4 in whom methylene blue is contra-indicated.
Laura Cooling
Department of Pathology, University of Michigan
Ann Arbor, Michigan
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